• Respiratory syncytial virus (RSV) infections are above the alert level. • Seasonal influenza (flu) infections are well ...
As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...